Archives: Agenda

• Patient reimbursement: how to relieve financial pressures on patients participating in trials
• Where are the main hurdles patients face and how can these be removed?
• Addressing low levels of health literacy in the patient population: how to improve communication
• Engaging patients and advocacy groups early on in the clinical trial design process

• How to keep up with rapid changes in technology?
• How do all the systems interact with each other?
• What is the ultimate goal?

• Navigating new regulations around clinical trials smoothly and successfully
• The impact of artificial intelligence: how far can we expect to move forward in the next 12 months?
• Patient centricity in clinical trials: how can burden be reduced in order to make trials easier for patients to participate in?
• How may geopolitical and geoeconomic events including the financial crisis, the Inflation Reduction Act and the upcoming election impact clinical trials in the US?
• Technological developments into 2025 and beyond: what changes can we expect to see in the next 3-5 years?

MODERATOR: Revati Tatake, Global Head of Pharma Research, Analysis and Competitive Intelligence, GlobalData Healthcare

• How AI and digitalization can support streamlining of clinical operations and improve efficiency
• Simple ways to implement tools such as GPT and GenAI
• Where can AI be utilized to minimize workloads and increase overall output?
• The regulatory landscape in the US for the use of AI in clinical trials: what do you need to know?
• Key limitations of GenAI and how these impact its potential uses for clinical trials in the US

• Budget considerations
• In house vs outsourced
• Site relationship management
• Effective risk-based approach
• Remote vs on-site

• How early should you begin planning study start up and site activation?
• Tips and tricks to reduce start up timelines for your trial
• Fostering a strong relationship with sites to accelerate study start up and reduce overall timelines

• Non-pathogenic, non-replicative, immune protected bacteria engineered to safely deliver biologic therapeutic payloads intracellular to targeted tissues
• Bacteria capable of delivering biologics as in mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas, independent of size
• Reaches tissues that cannot be targeted by viral vectors or lipid nanoparticles
• Efficiently target even hard-to-reach tissues and tumors
• Revolutionizes future of treatment by ensuring better outcomes for patients